LncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity
机构:[1]Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090[2]Department of Obstetrics and Gynecology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120[3]Department of Gynecology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032昆明医科大学附属第一医院[4]Department of Internal Medicine, People's Hospital of Dezhou, Dezhou, Shandong 253001[5]Clinical Nursing Staff Room, Department of Medicine, Dezhou University, Dezhou, Shandong 253023[6]Department of Obstetrics and Gynecology, The Second People's Hospital of Dongying, Dongying, Shandong 257335, P.R. China
第一作者机构:[1]Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090
共同第一作者:
通讯作者:
通讯机构:[1]Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090[*1]Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, 128 Shen‑Yang Road, Shanghai 200090, P.R. China
推荐引用方式(GB/T 7714):
WEIJUAN XIN,SHUTING ZHAO,XUESONG HAN,et al.LncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity[J].INTERNATIONAL JOURNAL OF ONCOLOGY.2020,57(1):355-363.doi:10.3892/ijo.2020.5046.
APA:
WEIJUAN XIN,SHUTING ZHAO,XUESONG HAN,PENG ZHAO,HUI YU...&KEQIN HUA.(2020).LncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity.INTERNATIONAL JOURNAL OF ONCOLOGY,57,(1)
MLA:
WEIJUAN XIN,et al."LncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity".INTERNATIONAL JOURNAL OF ONCOLOGY 57..1(2020):355-363